999 jili games 01
Former Barcelona Head Coach Takes Charge at Beijing GuoanThe sudden passing of the popular Chinese internet sensation "Liu Dabeili" has sent shockwaves through social media platforms and raised serious questions about the impact of the pursuit of beauty through cosmetic procedures. Liu Dabeili, known for her glamorous lifestyle and stunning appearance, tragically lost her life after undergoing a liposuction procedure at a local hospital.
49ers rule out QB Brock Purdy, DE Nick Bosa vs. PackersFurthermore, the meeting also underscored the importance of implementing targeted measures to address specific challenges in key sectors such as manufacturing, services, and agriculture. Policies to streamline regulatory procedures, reduce bureaucratic hurdles, and enhance market access for small and medium-sized enterprises were among the initiatives discussed to stimulate growth and create a more conducive business environment.
On November 21, De La Soul ’s surviving members, Kelvin “Posdnous” Mercer and Vincent “DJ Maseo” Mason, shocked fans by denouncing Marcus J. Moore’s new biography, High and Rising: A Book About De La Soul across their social media accounts. “We’ve been receiving congratulatory messages about a book titled ‘High & Rising,’” read the posts. “However, we want to make it absolutely clear: this is an unauthorized book, and we are not connected to it in any way.” The post went on to say, “If you choose to support this book, that’s your right. We just want it to be clear that we do not and we are exploring all of our legal options.” De La Soul insinuates they were blindsided by High and Rising’s publication on November 19. But in the book, which Harper Collins imprint Dey St. promotes as “the first-ever book about the trio,” Moore writes that he interviewed several onetime De La collaborators like the Jungle Brothers and DJ Premier but “the group didn’t participate.” ( High and Rising may be the first major biography about the group. But a critical biography published by J-Card Press, De La Soul by Dave Heaton, preceded it in July.) Throughout High and Rising ’s 200-plus pages, Moore not only writes about the Long Island trio’s history from a critical and cultural perspective, but also weaves in personal reminiscences of fandom, from hearing “Potholes in My Lawn” as an eight-year-old to interviewing the group in 2016. Moore finds solace in their music as he mourns the death of his mother, and closes with a heartfelt open letter to Dave “Trugoy the Dove” Jolicouer, who died on February 12, 2023 . Moore has contributed to Rolling Stone , among many other publications. In 2020, RS listed his first book The Butterfly Effect: How Kendrick Lamar Ignited the Soul of Black America as one of the best music books of the year . He’s currently an adjunct professor at New York University Tisch School of the Arts. When asked for comment, a spokesperson for Harper Collins responded, “Marcus J. Moore prefers not to give more life to the De La Soul reaction to the book, etc., and thus will take a pass on this interview.” In a Forbes profile, he discussed High and Rising ’s unique mix of musical history and autobiography, explaining , “Ultimately, we only get one crack at this thing (life) and I didn’t want to present a book that was overly cryptic for no reason. Who wants an overly scholarly De La Soul book? Those guys were fun.” Representatives for De La Soul could not be reached for comment. Editor’s picks The 100 Best TV Episodes of All Time The 250 Greatest Guitarists of All Time The 500 Greatest Albums of All Time The 200 Greatest Singers of All Time De La Soul’s unexpected broadside against High and Rising drew plenty of online condemnation. “As critics and journalists, we are accustomed to seeing our work criticized and questioned. To see artists (or their estates) attempt to equate unauthorized with libel is fucked up...but it’s also incredibly dangerous,” wrote longtime music journalist Gerrick Kennedy on Twitter/X . Tensions between journalists and rappers have often flared since hip-hop came of age in the late Eighties, when the mainstream media’s frequent distortions of the genre inspired righteous pushback like Public Enemy’s “Don’t Believe the Hype.” In the Nineties, critical magazine reviews and articles led to threats of violence or worse. Old heads of a certain age still gossip about when Masta Killa of Wu-Tang Clan sucker-punched Cheo H. Coker over a 1994 article in The Source . (Decades later, Masta Killa denied the incident took place.) Such conflicts seem rooted in misunderstanding, leading rap artists – many of whom rose out of impoverished circumstances – fearful over whether adverse publicity can damage their livelihood to (wrongly) lash out. Those old-school confrontations echo in the way A Tribe Called Quest denounced actor-director Michael Rapaport’s 2011 documentary Beats, Rhymes & Life: The Travels of A Tribe Called Quest for including heartbreaking fights between Q-Tip and the late Phife Dawg; and how Lil Wayne tried to sue Adam Bhala Lough over the 2009 cult doc The Carter , ostensibly over its raw scenes of substance abuse. But recent years have marked a subtle shift from self-righteous battles over reputation to less principled conflicts over branding control, like when Kanye West disowned his participation in Coodie & Chike’s 2022 documentary Jeen-Yuhs because he was denied final cut. This reflects an environment in which celebrities demand production credit and veto power over any content they’re involved in , journalistic integrity be damned. Related Content Mac Miller Estate to Drop Unreleased 2014 Album 'Balloonerism' Cher, Dave Matthews, Ozzy Osbourne Turn Back Time at Epic Rock Hall of Fame Ceremony Dave Chappelle Shares Heartfelt Story for A Tribe Called Quest Rock Hall Induction A Tribe Called Quest Honor Phife Dawg During Rock & Roll Hall of Fame Induction: 'Wish You Were Here' In the hip-hop literary world, the closest precedent to De La Soul’s complaint against Moore’s High and Rising may be Paul Cantor’s 2022 book Most Dope: The Extraordinary Life of Mac Miller . Even before it was finished, the late rapper’s mother, Karen Meyers, warned on Instagram in 2019, “To artists, management & friends: there is a writer doing a Mac Miller biography... We are not participating and prefer you don’t either if you personally knew Malcolm.” Then, when Most Dope was made available for pre-order in May 2021, Myers directed fans to ignore it in favor of a biography authorized by Mac Miller’s estate, Donna-Claire Chesman’s The Book of Mac . “[Cantor] chose to proceed against our polite insistence that he not do disservice to Malcolm’s legacy through writing a book without legitimate primary sources,” she wrote in a separate post. The negative publicity Mac Miller’s estate generated around Most Dope turned Cantor into a target of the beloved rapper’s fanbase. “They sent me death threats, called me names, and accused me of all sorts of things... Trolls bombarded sites like Goodreads, Barnes and Noble and Google Books, leaving one-star reviews and comments disparaging me and my book – despite having never read a single word of it,” Cantor later wrote . “How did writing a simple biography turn into something so toxic? The whole situation drove me into a crushing depression.” So far, De La Soul’s social media post hasn’t generated a similarly venomous overreaction: High and Rising currently enjoys a 4.03 rating on Goodreads . However, it betrays similar illusions that books are just another form of intellectual property that an artist should benefit from. “For years, you’ve stood with us in our fight for ownership of our catalog,” writes the group, referring to their years-long struggle over streaming rights. “Our story will be told in our words, in our way, with the style you’ve come to know and love. Until then, we encourage you to indulge in the authentic D.A.I.S.Y. Age by supporting projects backed by us.” They then hint at a spring 2025 release date for “that authentic ‘De La’.” But Moore isn’t denying De La Soul due profits from intellectual property. He’s commenting with loving criticism on a musical ensemble whose words, images, and creativity impacted generations of lives, including his own. Writers should be allowed to observe, critique, and analyze the world around them, regardless of the intellectual merit of their conclusions. A veiled threat of a lawsuit against High and Rising runs not only contrary to U.S. fair use copyright laws, but also threatens to diminish the spirit of communal joy and moral responsibility that De La Soul has so wonderfully conveyed through their art.Kyiv accuses Russia of launching intercontinental ballistic missile attack
In the bustling city streets, a peculiar sight caught the attention of passersby – Lín Jìng'ēn, a once renowned actress, now reduced to a beggar seeking food. Her appearance was disheveled, her eyes hauntingly strange as she approached strangers for help, only to be met with cold rejections.None
None
John Fetterman Becomes First Senate Democrat On Truth Social
As the day transitions into evening, the mercury will once again plummet, reminding us of the importance of staying warm. When you return home after a long day out, take the time to relax and unwind in a cozy environment. Consider brewing a hot cup of tea or soup to warm yourself from the inside out. In the evenings, when the temperature drops dramatically, it is advisable to close your windows and draw your curtains to keep the warmth inside.
However, with speculation mounting about possible exits, Liverpool has wasted no time in identifying potential replacements. Florian Thauvin, the talented French winger currently plying his trade at Tigres UANL in Mexico, has emerged as a leading candidate to fill the void that would be left by Salah's departure. Thauvin's combination of skill, pace, and creativity has caught the attention of Liverpool's scouting team, who view him as a player capable of making an immediate impact in the Premier League.Parkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma 11-21-2024 08:50 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market. The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years. •Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment •Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years. •In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms. •In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). •In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. •In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations. Parkinson's Disease Overview Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control. Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include: •KM-819: FAScinate Therapeutics •Prasinezumab: Hoffmann-La Roche •P2B001: Pharma Two B Ltd. •NPT1220-478: Neuropore Therapies, Inc. •Dapansutrile: Olatec Therapeutics •UCB7853: UCB Biopharma •UB-312: Vaxxinity •Emrusolmin: Modag •PT320: Peptron •KDT-3594: Kissei Pharmaceutical •Tavapadon: Cerevel Therapeutics Parkinson's Disease Route of Administration Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Inhalation •Inhalation/Intravenous/Oral •Intranasal •Intravenous •Intravenous/ Subcutaneous •NA •Oral •Oral/intranasal/subcutaneous •Parenteral •Subcutaneous Parkinson's Disease Molecule Type Parkinson's Disease Products have been categorized under various Molecule types, such as •Antibody •Antisense oligonucleotides •Immunotherapy •Monoclonal antibody •Peptides •Protein •Recombinant protein •Small molecule •Stem Cell •Vaccine Parkinson's Disease Pipeline Therapeutics Assessment •Parkinson's Disease Assessment by Product Type •Parkinson's Disease By Stage and Product Type •Parkinson's Disease Assessment by Route of Administration •Parkinson's Disease By Stage and Route of Administration •Parkinson's Disease Assessment by Molecule Type •Parkinson's Disease by Stage and Molecule Type DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parkinson's Disease Therapeutics Market include: Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others. Parkinson's Disease Pipeline Analysis: The Parkinson's Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment. •Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parkinson's Disease Pipeline Market Drivers •Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market. Parkinson's Disease Pipeline Market Barriers •However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth. Scope of Parkinson's Disease Pipeline Drug Insight •Coverage: Global •Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others •Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others •Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies •Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parkinson's Disease Report Introduction 2. Parkinson's Disease Executive Summary 3. Parkinson's Disease Overview 4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment 5. Parkinson's Disease Pipeline Therapeutics 6. Parkinson's Disease Late Stage Products (Phase II/III) 7. Parkinson's Disease Mid Stage Products (Phase II) 8. Parkinson's Disease Early Stage Products (Phase I) 9. Parkinson's Disease Preclinical Stage Products 10. Parkinson's Disease Therapeutics Assessment 11. Parkinson's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parkinson's Disease Key Companies 14. Parkinson's Disease Key Products 15. Parkinson's Disease Unmet Needs 16 . Parkinson's Disease Market Drivers and Barriers 17. Parkinson's Disease Future Perspectives and Conclusion 18. Parkinson's Disease Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
NASHVILLE, Tenn. (WTVF) — A year ago the Nashville Predators made a stunning turnaround, shooting up the Central Division standings with a franchise-record 18-game point streak in February and March to help secure a playoff berth. The Preds are going to need a similar turnaround after amassing the fewest points in the NHL through the first third of the season. Nashville currently sits in last place in the Central Division and is in the middle of an eight-game losing streak as it faced the Stars in Dallas. Predators play-by-play announcer Willy Daunic shares his thoughts on why the offense has failed to produce so far this season and what has to happen for the team to climb out of the cellar. The Predators road trip continues Saturday in Colorado against the Avalanche in a game you can watch on NewsChannel 5 at 8 p.m. Coverage begins with Predators Pursuit of Glory with Steve Layman and Jon Burton at 7 p.m. followed by Predators LIVE from Denver leading up to puck drop. Get NewsChannel 5 Now , wherever, whenever, always free.Freiburg survives late onslaught to beat Wolfsburg in Bundesliga thriller
Former Barcelona Head Coach Takes Charge at Beijing GuoanThe sudden passing of the popular Chinese internet sensation "Liu Dabeili" has sent shockwaves through social media platforms and raised serious questions about the impact of the pursuit of beauty through cosmetic procedures. Liu Dabeili, known for her glamorous lifestyle and stunning appearance, tragically lost her life after undergoing a liposuction procedure at a local hospital.
49ers rule out QB Brock Purdy, DE Nick Bosa vs. PackersFurthermore, the meeting also underscored the importance of implementing targeted measures to address specific challenges in key sectors such as manufacturing, services, and agriculture. Policies to streamline regulatory procedures, reduce bureaucratic hurdles, and enhance market access for small and medium-sized enterprises were among the initiatives discussed to stimulate growth and create a more conducive business environment.
On November 21, De La Soul ’s surviving members, Kelvin “Posdnous” Mercer and Vincent “DJ Maseo” Mason, shocked fans by denouncing Marcus J. Moore’s new biography, High and Rising: A Book About De La Soul across their social media accounts. “We’ve been receiving congratulatory messages about a book titled ‘High & Rising,’” read the posts. “However, we want to make it absolutely clear: this is an unauthorized book, and we are not connected to it in any way.” The post went on to say, “If you choose to support this book, that’s your right. We just want it to be clear that we do not and we are exploring all of our legal options.” De La Soul insinuates they were blindsided by High and Rising’s publication on November 19. But in the book, which Harper Collins imprint Dey St. promotes as “the first-ever book about the trio,” Moore writes that he interviewed several onetime De La collaborators like the Jungle Brothers and DJ Premier but “the group didn’t participate.” ( High and Rising may be the first major biography about the group. But a critical biography published by J-Card Press, De La Soul by Dave Heaton, preceded it in July.) Throughout High and Rising ’s 200-plus pages, Moore not only writes about the Long Island trio’s history from a critical and cultural perspective, but also weaves in personal reminiscences of fandom, from hearing “Potholes in My Lawn” as an eight-year-old to interviewing the group in 2016. Moore finds solace in their music as he mourns the death of his mother, and closes with a heartfelt open letter to Dave “Trugoy the Dove” Jolicouer, who died on February 12, 2023 . Moore has contributed to Rolling Stone , among many other publications. In 2020, RS listed his first book The Butterfly Effect: How Kendrick Lamar Ignited the Soul of Black America as one of the best music books of the year . He’s currently an adjunct professor at New York University Tisch School of the Arts. When asked for comment, a spokesperson for Harper Collins responded, “Marcus J. Moore prefers not to give more life to the De La Soul reaction to the book, etc., and thus will take a pass on this interview.” In a Forbes profile, he discussed High and Rising ’s unique mix of musical history and autobiography, explaining , “Ultimately, we only get one crack at this thing (life) and I didn’t want to present a book that was overly cryptic for no reason. Who wants an overly scholarly De La Soul book? Those guys were fun.” Representatives for De La Soul could not be reached for comment. Editor’s picks The 100 Best TV Episodes of All Time The 250 Greatest Guitarists of All Time The 500 Greatest Albums of All Time The 200 Greatest Singers of All Time De La Soul’s unexpected broadside against High and Rising drew plenty of online condemnation. “As critics and journalists, we are accustomed to seeing our work criticized and questioned. To see artists (or their estates) attempt to equate unauthorized with libel is fucked up...but it’s also incredibly dangerous,” wrote longtime music journalist Gerrick Kennedy on Twitter/X . Tensions between journalists and rappers have often flared since hip-hop came of age in the late Eighties, when the mainstream media’s frequent distortions of the genre inspired righteous pushback like Public Enemy’s “Don’t Believe the Hype.” In the Nineties, critical magazine reviews and articles led to threats of violence or worse. Old heads of a certain age still gossip about when Masta Killa of Wu-Tang Clan sucker-punched Cheo H. Coker over a 1994 article in The Source . (Decades later, Masta Killa denied the incident took place.) Such conflicts seem rooted in misunderstanding, leading rap artists – many of whom rose out of impoverished circumstances – fearful over whether adverse publicity can damage their livelihood to (wrongly) lash out. Those old-school confrontations echo in the way A Tribe Called Quest denounced actor-director Michael Rapaport’s 2011 documentary Beats, Rhymes & Life: The Travels of A Tribe Called Quest for including heartbreaking fights between Q-Tip and the late Phife Dawg; and how Lil Wayne tried to sue Adam Bhala Lough over the 2009 cult doc The Carter , ostensibly over its raw scenes of substance abuse. But recent years have marked a subtle shift from self-righteous battles over reputation to less principled conflicts over branding control, like when Kanye West disowned his participation in Coodie & Chike’s 2022 documentary Jeen-Yuhs because he was denied final cut. This reflects an environment in which celebrities demand production credit and veto power over any content they’re involved in , journalistic integrity be damned. Related Content Mac Miller Estate to Drop Unreleased 2014 Album 'Balloonerism' Cher, Dave Matthews, Ozzy Osbourne Turn Back Time at Epic Rock Hall of Fame Ceremony Dave Chappelle Shares Heartfelt Story for A Tribe Called Quest Rock Hall Induction A Tribe Called Quest Honor Phife Dawg During Rock & Roll Hall of Fame Induction: 'Wish You Were Here' In the hip-hop literary world, the closest precedent to De La Soul’s complaint against Moore’s High and Rising may be Paul Cantor’s 2022 book Most Dope: The Extraordinary Life of Mac Miller . Even before it was finished, the late rapper’s mother, Karen Meyers, warned on Instagram in 2019, “To artists, management & friends: there is a writer doing a Mac Miller biography... We are not participating and prefer you don’t either if you personally knew Malcolm.” Then, when Most Dope was made available for pre-order in May 2021, Myers directed fans to ignore it in favor of a biography authorized by Mac Miller’s estate, Donna-Claire Chesman’s The Book of Mac . “[Cantor] chose to proceed against our polite insistence that he not do disservice to Malcolm’s legacy through writing a book without legitimate primary sources,” she wrote in a separate post. The negative publicity Mac Miller’s estate generated around Most Dope turned Cantor into a target of the beloved rapper’s fanbase. “They sent me death threats, called me names, and accused me of all sorts of things... Trolls bombarded sites like Goodreads, Barnes and Noble and Google Books, leaving one-star reviews and comments disparaging me and my book – despite having never read a single word of it,” Cantor later wrote . “How did writing a simple biography turn into something so toxic? The whole situation drove me into a crushing depression.” So far, De La Soul’s social media post hasn’t generated a similarly venomous overreaction: High and Rising currently enjoys a 4.03 rating on Goodreads . However, it betrays similar illusions that books are just another form of intellectual property that an artist should benefit from. “For years, you’ve stood with us in our fight for ownership of our catalog,” writes the group, referring to their years-long struggle over streaming rights. “Our story will be told in our words, in our way, with the style you’ve come to know and love. Until then, we encourage you to indulge in the authentic D.A.I.S.Y. Age by supporting projects backed by us.” They then hint at a spring 2025 release date for “that authentic ‘De La’.” But Moore isn’t denying De La Soul due profits from intellectual property. He’s commenting with loving criticism on a musical ensemble whose words, images, and creativity impacted generations of lives, including his own. Writers should be allowed to observe, critique, and analyze the world around them, regardless of the intellectual merit of their conclusions. A veiled threat of a lawsuit against High and Rising runs not only contrary to U.S. fair use copyright laws, but also threatens to diminish the spirit of communal joy and moral responsibility that De La Soul has so wonderfully conveyed through their art.Kyiv accuses Russia of launching intercontinental ballistic missile attack
In the bustling city streets, a peculiar sight caught the attention of passersby – Lín Jìng'ēn, a once renowned actress, now reduced to a beggar seeking food. Her appearance was disheveled, her eyes hauntingly strange as she approached strangers for help, only to be met with cold rejections.None
None
John Fetterman Becomes First Senate Democrat On Truth Social
As the day transitions into evening, the mercury will once again plummet, reminding us of the importance of staying warm. When you return home after a long day out, take the time to relax and unwind in a cozy environment. Consider brewing a hot cup of tea or soup to warm yourself from the inside out. In the evenings, when the temperature drops dramatically, it is advisable to close your windows and draw your curtains to keep the warmth inside.
However, with speculation mounting about possible exits, Liverpool has wasted no time in identifying potential replacements. Florian Thauvin, the talented French winger currently plying his trade at Tigres UANL in Mexico, has emerged as a leading candidate to fill the void that would be left by Salah's departure. Thauvin's combination of skill, pace, and creativity has caught the attention of Liverpool's scouting team, who view him as a player capable of making an immediate impact in the Premier League.Parkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma 11-21-2024 08:50 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market. The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years. •Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment •Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years. •In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms. •In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). •In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. •In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations. Parkinson's Disease Overview Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control. Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include: •KM-819: FAScinate Therapeutics •Prasinezumab: Hoffmann-La Roche •P2B001: Pharma Two B Ltd. •NPT1220-478: Neuropore Therapies, Inc. •Dapansutrile: Olatec Therapeutics •UCB7853: UCB Biopharma •UB-312: Vaxxinity •Emrusolmin: Modag •PT320: Peptron •KDT-3594: Kissei Pharmaceutical •Tavapadon: Cerevel Therapeutics Parkinson's Disease Route of Administration Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Inhalation •Inhalation/Intravenous/Oral •Intranasal •Intravenous •Intravenous/ Subcutaneous •NA •Oral •Oral/intranasal/subcutaneous •Parenteral •Subcutaneous Parkinson's Disease Molecule Type Parkinson's Disease Products have been categorized under various Molecule types, such as •Antibody •Antisense oligonucleotides •Immunotherapy •Monoclonal antibody •Peptides •Protein •Recombinant protein •Small molecule •Stem Cell •Vaccine Parkinson's Disease Pipeline Therapeutics Assessment •Parkinson's Disease Assessment by Product Type •Parkinson's Disease By Stage and Product Type •Parkinson's Disease Assessment by Route of Administration •Parkinson's Disease By Stage and Route of Administration •Parkinson's Disease Assessment by Molecule Type •Parkinson's Disease by Stage and Molecule Type DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parkinson's Disease Therapeutics Market include: Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others. Parkinson's Disease Pipeline Analysis: The Parkinson's Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment. •Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parkinson's Disease Pipeline Market Drivers •Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market. Parkinson's Disease Pipeline Market Barriers •However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth. Scope of Parkinson's Disease Pipeline Drug Insight •Coverage: Global •Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others •Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others •Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies •Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parkinson's Disease Report Introduction 2. Parkinson's Disease Executive Summary 3. Parkinson's Disease Overview 4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment 5. Parkinson's Disease Pipeline Therapeutics 6. Parkinson's Disease Late Stage Products (Phase II/III) 7. Parkinson's Disease Mid Stage Products (Phase II) 8. Parkinson's Disease Early Stage Products (Phase I) 9. Parkinson's Disease Preclinical Stage Products 10. Parkinson's Disease Therapeutics Assessment 11. Parkinson's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parkinson's Disease Key Companies 14. Parkinson's Disease Key Products 15. Parkinson's Disease Unmet Needs 16 . Parkinson's Disease Market Drivers and Barriers 17. Parkinson's Disease Future Perspectives and Conclusion 18. Parkinson's Disease Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
NASHVILLE, Tenn. (WTVF) — A year ago the Nashville Predators made a stunning turnaround, shooting up the Central Division standings with a franchise-record 18-game point streak in February and March to help secure a playoff berth. The Preds are going to need a similar turnaround after amassing the fewest points in the NHL through the first third of the season. Nashville currently sits in last place in the Central Division and is in the middle of an eight-game losing streak as it faced the Stars in Dallas. Predators play-by-play announcer Willy Daunic shares his thoughts on why the offense has failed to produce so far this season and what has to happen for the team to climb out of the cellar. The Predators road trip continues Saturday in Colorado against the Avalanche in a game you can watch on NewsChannel 5 at 8 p.m. Coverage begins with Predators Pursuit of Glory with Steve Layman and Jon Burton at 7 p.m. followed by Predators LIVE from Denver leading up to puck drop. Get NewsChannel 5 Now , wherever, whenever, always free.Freiburg survives late onslaught to beat Wolfsburg in Bundesliga thriller
-
"> -
"> -
"> -
">
